Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring
to address rare genetic metabolic disorders through a pipeline of oral small molecules with diseasemodifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros'
proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage
diseases for which there are no...
Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring
to address rare genetic metabolic disorders through a pipeline of oral small molecules with diseasemodifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros'
proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage
diseases for which there are no effective therapies today. This orally available azasugar compound
interferes with the metabolism of glycolipids and uniquely affects several key disease pathways
through a dual mode of action.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.